Abstract
While radiation is an effective oncologic therapy, killing cancer by inducing DNA double-strand breaks (DSBs), it lacks specificity for neoplastic cells. We have previously adapted the CRISPR/Cas9 gene-editing technology as a cancer-specific treatment modality targeting somatic mutations in pancreatic cancer (PC). However, its tumoricidal potential remains unclear, especially in comparison with therapeutic doses of radiation. Here, we demonstrate that CRISPR/Cas9-induced DSBs are more cytotoxic in PCs than a comparable number of radiation-induced DSBs. We observed more than 90% tumor growth inhibition by targeting 9 sites with cancer-specific sgRNAs. Through both bioinformatics and cytogenetics analyses, we found that CRISPR/Cas9-induced DSBs triggered ongoing chromosomal rearrangements, with 87% of structural variants not directly produced from the initial CRISPR/Cas9-induced DSBs, and chromosomal instability peaking before cell death. By comparing the cytotoxicity of CRISPR/Cas9- and radiation-induced DSBs, we demonstrated that the number of DSBs required to achieve equitoxic effects was approximately 3 times higher for radiation than CRISPR/Cas9. Finally, we showed that PC cells that had survived CRISPR/Cas9 targeting retained susceptibility to subsequent CRISPR/Cas9-induced DSBs at different genomic sites with more than 87% growth inhibition. Together, our data support the therapeutic potential of CRISPR/Cas9 as an anticancer strategy. The CRISPR-Cas9 system can be adapted into a cancer killing strategy by inducing precise and unrecoverable DNA damage.
All Related Versions
Funding Information
  • National Institutes of Health (R21CA164592,P50CA62924)
  • The Sol Goldman Pancreatic Cancer Research Center (The Sol Goldman Pancreatic Cancer Research Center)
  • PanCan/AACR Innovation Award (PanCan/AACR Innovation Award)
  • The Stringer Foundation (The STRINGER Foundation)
  • Casimir H. Zgonina Family Endowment for Pancreatic Cancer Research (Casimir H. Zgonina Family Endowment for Pancreatic Cancer Research)
  • Dennis Troper and Susan Wojcicki (Dennis Troper)
  • Dennis Troper and Susan Wojcicki (Susan Wojcicki)
  • Dick Knox/Cliff Minor Fund (Dick Knox/Cliff Minor Fund)
  • Edward A. Goldsmith Pancreatic Cancer Research Fund (Edward A. Goldsmith Pancreatic Cancer Research Fund)
  • Elaine Crispen Sawyer Endowment (Elaine Crispen Sawyer Endowment)
  • Elaine T. Koehler Pancreatic Cancer Research Fund (Elaine T. Koehler Pancreatic Cancer Research Fund)
  • Eve Stancik Memorial Fund (Eve Stancik Memorial Fund)
  • George Rubis Endowment for Pancreatic Cancer Research (George Rubis Endowment for Pancreatic Cancer Research)
  • Hilda Buchfeller Yost Young Investigator’s Fund (Hilda Buchfeller Yost Young Investigator’s Fund)
  • James S. McFarland Endowment for Pancreatic Cancer Research (James S. McFarl)
  • James S. McFarland Endowment for Pancreatic Cancer Research (Endowment for Pancreatic Cancer Research)
  • John J. Lussier Pancreatic Cancer Research Fund (John J. Lussier Pancreatic Cancer Research Fund)
  • Linda C. Talecki Gallbladder Cancer Research Fund (Linda C. Talecki Gallbladder Cancer Research Fund)
  • Mary M. Graf Memorial Endowment Fund for Gallbladder Cancer (Mary M. Graf Memorial Endowment Fund for Gallbladder Cancer)
  • Mary Lou Wootton Endowment (Mary Lou Wootton Endowment)
  • Professor J. Mayo Greenberg and Dr. Samuel L. Slovin Endowment (Professor J. Mayo Greenberg)
  • Professor J. Mayo Greenberg and Dr. Samuel L. Slovin Endowment (Dr. Samuel L. Slovin Endowment)
  • Rawlings Family Pancreatic Cancer Research Fund (Rawlings Family Pancreatic Cancer Research Fund)
  • National Cancer Institute CCSG (P30CA006973)

This publication has 75 references indexed in Scilit: